Trenchant & Autolomous Partner to Accelerate Cell & Gene Therapy Fully-Automated CAR-T Bioprocessing Platform Aids Scalability
As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated manufacturing Trenchant BioSystems and Autolomous to Combine Platforms for
Under the partnership, the companies will combine fully automated and digitalized technologies aimed at reducing CGT manufacturing timelines Cells video 1 Trenchant Bio is making cell and gene therapies (CGT) more affordable and accessible to patients. We were founded in 2022 to create cell therapy manufacturing
Cancer cells video 1 sunrise video Trenchant, Inc.
Trenchant Biosystems specializes in developing scalable and efficient cell therapy manufacturing technologies that streamline processes, Cell and Gene Therapy Manufacturing Challenges & Solutions
Supplier News: Fujifilm Irvine Scientific, Pace Life Sciences As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated CGT manufacturing Addressing major obstacles in the development and manufacturing of CGTs with Jon Ellis, CEO of Trenchant BioSystems.
Philip H. Coelho, currently serving as Chairman and CTO of Trenchant BioSystems, Inc. is an engineer/ inventor, educated at the University of California, Davis. Private equity investments demand strategic growth, operational excellence, and measurable outcomes. At Trenchant, we specialize in helping businesses achieve
The new industry deals progressing drug discovery - Drug Discovery As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into their automated CGT Trenchant Biosystems
Trenchant BioSystems, tells GEN. CGT-in-a-box. To address those issues, Trenchant is developing a fully-automated cell therapy manufacturing Company — Trenchant Biosystems Philip Coelho - Chairman & CTO of Trenchant BioSystems, Inc